GlassScriptPhysician profile
George A Resta
NPI 1720078215
$3,875.89
in general payments reported to CMS, 2019-2025
36 companies · $573 in 2025
The $573 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $492 · 2021: $1,197 · 2022: $452 · 2023: $220 · 2024: $532 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $972.83 | 2019-2025 | |
| Aspira Women'S Health INC | $308.68 | 2021 | |
| Astellas Pharma US INC | $304.17 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $250.51 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $201.98 | 2021-2025 | |
| Millicent US INC | $190.40 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Allergan, INC. | $158.59 | 2019-2021 | |
| Coopersurgical, INC. | $158.30 | 2019-2025 | Paragard T 380a, Mara Console |
| Mylan Pharmaceuticals INC. | $104.11 | 2019-2022 | |
| Caldera Medical, INC | $101.74 | 2025 | |
| Medtronic, INC. | $94.50 | 2024 | Sonicision |
| Avion Pharmaceuticals | $94.39 | 2020-2022 | |
| Daiichi Sankyo INC. | $83.63 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.05 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $65.03 | 2020-2025 | Gardasil 9 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.59 | 2021-2025 | Evenity, Prolia |
| Myovant Sciences INC. | $62.13 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $61.11 | 2023-2024 | Myfembree, Gemtesa |
| Meditrina | $60.99 | 2022-2025 | |
| Therapeuticsmd, INC. | $56.00 | 2020-2021 | |
| Lumenis, INC | $45.01 | 2021 | |
| Ethicon US, LLC | $41.54 | 2025 | Ethicon, Stratafix |
| Exact Sciences Corporation | $40.31 | 2023-2025 | Cologuard Collection Kit |
| Exeltis, USA INC. | $35.10 | 2021 | |
| Sage Therapeutics, LLC | $32.34 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $30.18 | 2024 | |
| Dexcom, INC. | $29.43 | 2025 | Dexcom G6 Transmitter |
| Coloplast Corp | $27.79 | 2024 | |
| Evofem Biosciences, INC. | $25.63 | 2021-2022 | |
| Eisai INC. | $20.06 | 2021 | |
| Kerecis Limited | $19.33 | 2022 | |
| Hologic Sales and Service, LLC | $17.52 | 2025 | Novasure, Myosure Tissue Removal Device |
| Cumberland Pharmaceuticals, INC. | $17.46 | 2020 | |
| Medicem INC. | $13.36 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Resta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.